NRG-LU005

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Principal Investigator

Kristin A. Higgins

Co-Principal Investigator(s)

Helen J. Ross

Status

Disease Site

Lung [LU] Small Cell

Phase

III

Developmental Therapeutics

No

Primary Objective

To compare overall survival (OS) for patients with LS-SCLC treated with chemoradiation +/- atezolizumab.

Patient Population

Patients with pathologically (histologically or cytologically) proven diagnosis of limited stage (Tx, T1-T4, N0-3, M0) small cell lung cancer (LS-SCLC) who have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry.

Target Accrual

506